Cargando…

P1116: SAFETY, PHARMACOKINETIC (PK), PHARMACODYNAMIC (PD) AND ACTIVITY OF THE HIGHLY SELECTIVE PHOSPHOINOSITIDE 3-KINASE INHIBITOR DELTA (PI3KΔ) INHIBITOR IOA-244 IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL)

Detalles Bibliográficos
Autores principales:	Carlostella, C., Lahn, M., Hammett, T., van der Veen, L., Johnson, Z., Pickering, C., Santoro, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429685/ http://dx.doi.org/10.1097/01.HS9.0000847332.17703.45

Ejemplares similares

P1114: HIGHLY SELECTIVE ALLOSTERIC MODULATOR OF THE PHOSPHOINOSITIDE 3-KINASE DELTA (PI3KΔ) ROGINOLISIB (IOA-244) IN A DOSE ESCALATION STUDY OF PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA (FL)
por: Carlo-Stella, Carmelo, et al.
Publicado: (2023)

IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
por: Johnson, Zoë, et al.
Publicado: (2023)

Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors
por: Deken, M.A., et al.
Publicado: (2023)

Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models
por: Centonze, Matteo, et al.
Publicado: (2023)

Correction: Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models
por: Centonze, Matteo, et al.
Publicado: (2023)

Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia
por: Shey, Susan, et al.
Publicado: (2021)

Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)
por: Huang, Xueqin, et al.
Publicado: (2023)

Past, present and future of IOA from my eyes and mind
por: Raza, HKT
Publicado: (2008)

To propose adding index of achievement (IOA) to IMRT QA process
por: Kim, Dong-Su, et al.
Publicado: (2018)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells
por: Kawase, Tatsuya, et al.
Publicado: (2019)

The t(14;18) translocation is absent from endothelial and follicular dendritic cells of follicular lymphoma (FL) and shows heterogeneous presence in preserved FL mantle zones
por: Kosmidis, Perikles, et al.
Publicado: (2018)

Sex Determination Using Inion-Opistocranium-Asterion (IOA) Triangle in Nigerians' Skulls
por: Orish, C. N., et al.
Publicado: (2014)

Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling
por: Maffucci, Tania, et al.
Publicado: (2020)

Phosphoinositide 3-kinase inhibitors are effective therapeutic drugs for the treatment of hepatocellular carcinoma?
por: Park, Jeong Su, et al.
Publicado: (2020)

ODP244 SGLT2 Inhibitor-Induced Euglycemic DKA and its Challenges
por: Penna, Laurianne El Musa, et al.
Publicado: (2022)

Identification of Novel Piperazinylquinoxaline Derivatives as Potent Phosphoinositide 3-Kinase (PI3K) Inhibitors
por: Wu, Peng, et al.
Publicado: (2012)

Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements
por: Bertucci, Alexandre, et al.
Publicado: (2023)

Thermal evolution of Andean iron oxide–apatite (IOA) deposits as revealed by magnetite thermometry
por: Palma, Gisella, et al.
Publicado: (2021)

Non-Clinical Toxicology Evaluation of the Novel Non-ATP Competitive Oral PI3 Kinase Delta Inhibitor Roginolisib
por: van der Veen, Lars, et al.
Publicado: (2023)

The Novel Therapeutic Effect of Phosphoinositide 3-Kinase-γ Inhibitor AS605240 in Autoimmune Diabetes
por: Azzi, Jamil, et al.
Publicado: (2012)

Initiation of human astrovirus type 1 infection was blocked by inhibitors of phosphoinositide 3-kinase
por: Tange, Shoichiro, et al.
Publicado: (2013)

Effects of a Phosphoinositide-3-Kinase Inhibitor on Anaplastic Thyroid Cancer Stem Cells
por: Bozorg-Ghalati, Farzaneh, et al.
Publicado: (2017)

Sodium-Glucose Cotransporter-2 Inhibitors for Hyperglycemia in Phosphoinositide 3-kinase Pathway Inhibition
por: Weintraub, Michael A, et al.
Publicado: (2023)

MON-LB128 Phosphoinositide 3-Kinase (PI3K) Inhibitor Induced Hyperglycemia With Alpelisib
por: Barsukova, Yuliya, et al.
Publicado: (2020)

Rebunching Run 1116 MD R1 - 24.04.1980
por: Ciapala, Edmond
Publicado: (1980)

1116 Microstructural & functional changes in the placenta during the COVID-19 pandemic
por: Andescavage, Nickie N., et al.
Publicado: (2021)

PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging
por: Irwin, Christopher P., et al.
Publicado: (2014)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
por: Huw, L-Y, et al.
Publicado: (2013)

Effects of Novel Isoform-Selective Phosphoinositide 3-Kinase Inhibitors on Natural Killer Cell Function
por: Yea, Sung Su, et al.
Publicado: (2014)

Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor–Induced Hyperglycemia: A Case Report
por: Bowman, Christopher, et al.
Publicado: (2017)

Targeted delivery of a phosphoinositide 3‐kinase γ inhibitor to restore organ function in sepsis
por: Press, Adrian T, et al.
Publicado: (2021)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality check
por: Zeitlinger, Markus, et al.
Publicado: (2023)

Application of An Improved HPLC-FL Method to Screen Serine Palmitoyl Transferase Inhibitors
por: Bertini, Simone, et al.
Publicado: (2017)

Identification of Novel Thiazolo[5,4-b]Pyridine Derivatives as Potent Phosphoinositide 3-Kinase Inhibitors
por: Xia, Liang, et al.
Publicado: (2020)

Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases
por: Apsel, Beth, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_2b79t8tlrbklltu0h5caf0avo7